803 related articles for article (PubMed ID: 23087408)
1. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Chen DS; Irving BA; Hodi FS
Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
[TBL] [Abstract][Full Text] [Related]
2. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
4. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive markers for the new immunotherapies.
Mahoney KM; Atkins MB
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():39-48. PubMed ID: 25384886
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
8. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
10. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Gettinger S; Herbst RS
Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Sundararajan S; Vogelzang NJ
Future Oncol; 2015; 11(16):2299-306. PubMed ID: 26260808
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
14. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
15. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Remon J; Chaput N; Planchard D
Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
[TBL] [Abstract][Full Text] [Related]
16. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
18. Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.
Sznol M
Cancer J; 2014; 20(4):290-5. PubMed ID: 25098290
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
